8-K Announcements
6Material company update
Apr 7, 2026·SEC
Material company update
Mar 20, 2026·SEC
Material company update
Mar 17, 2026·SEC
Abeona Therapeutics Inc.(ABEO)Earnings, Financials & Key Ratios
ABEO•NASDAQ
$5.77
$318M mkt cap·5.7× P/E·Price updated May 7, 2026
AboutAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.Show more
- Revenue$6M
- EBITDA-$86M-40.1%
- Net Income$71M+211.7%
- EPS (Diluted)1.01+165.2%
- Gross Margin73.68%
- EBITDA Margin-1475.69%
- Operating Margin-1536.91%
- Net Margin1223.08%
- ROE70.05%+132.3%
- ROIC-89.77%+53.9%
- Debt/Equity0.16-70.0%
- Interest Coverage-23.92-56.7%
ABEO Key Insights
Abeona Therapeutics Inc. (ABEO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Negative free cash flow
- ✗Sales declining 10.3% over 5 years
- ✗Shares diluted 61.1% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ABEO Price & Volume
Abeona Therapeutics Inc. (ABEO) stock price & volume — 10-year historical chart
Loading chart...
ABEO Growth Metrics
Abeona Therapeutics Inc. (ABEO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years18.79%
5 Years-10.26%
3 Years60.26%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM211.69%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM153.98%
Return on Capital
10 Years-61.39%
5 Years-86.19%
3 Years-80.43%
Last Year-63.36%
ABEO Recent Earnings
Abeona Therapeutics Inc. (ABEO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 1/12 qtrs (50%)
Q2 2026Latest
Mar 17, 2026EPS
$0.34
Est $0.35
+2.9%
Revenue
$5M
Est $4M
+22.0%
Q4 2025
Nov 12, 2025EPS
$0.10
Est $0.27
+63.0%
Revenue
—
Est $6M
Q3 2025
Aug 14, 2025EPS
$1.71
Est $0.39
+538.5%
Revenue
$400,000
Est $7M
-93.9%
Q2 2025
May 15, 2025EPS
$0.24
Est $0.35
+31.4%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 17, 2026 | $0.34vs $0.35+2.9% | $5Mvs $4M+22.0% |
| Q4 2025 | Nov 12, 2025 | $0.10vs $0.27+63.0% | —vs $6M |
| Q3 2025 | Aug 14, 2025 | $1.71vs $0.39+538.5% | $400,000vs $7M-93.9% |
| Q2 2025 | May 15, 2025 | $0.24vs $0.35+31.4% | — |
Based on last 12 quarters of dataView full earnings history →
ABEO Peer Comparison
Abeona Therapeutics Inc. (ABEO) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KRYS | 8.75B | 296.70 | 43.38 | 33.94% | 53.92% | 19.25% | 0.01 | |
 RARE | 2.57B | 26.13 | -4.48 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 ACAD | 3.86B | 22.57 | 9.85 | 11.87% | 34.3% | 35.65% | 0.04 | |
 RCKT | 397.53M | 3.67 | -1.83 | -80.49% | 0.09 | |||
 BEAM | 3.23B | 31.47 | -38.85 | 120.01% | -49.17% | -5.89% | 0.24 | |
 SGMO | 21.54M | 0.10 | -0.21 | -67.2% | -331.28% | -8.14% | 1.34 | |
 CRSP | 5.06B | 52.42 | -8.10 | -89.97% | -138.57% | -30.88% | 0.21 |
Compare ABEO vs Peers
Abeona Therapeutics Inc. (ABEO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ABEO Income Statement
Abeona Therapeutics Inc. (ABEO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 837K | 3M | 0 | 10M | 3M | 1.41M | 3.5M | 0 | 5.82M |
| Revenue Growth % | -5.85% | 258.18% | -100% | - | -70% | -52.87% | 147.52% | -100% | - |
| Cost of Goods Sold | 16.99M | 38.7M | 48.57M | 0 | 0 | 450K | 1.6M | 2.91M | 1.53M |
| COGS % of Revenue | 2029.75% | 1290.79% | - | - | - | 31.82% | 45.86% | - | 26.32% |
| Gross Profit | -16.15M▲ 0% | -35.7M▼ 121.0% | -48.57M▼ 36.0% | 10M▲ 120.6% | 3M▼ 70.0% | 964K▼ 67.9% | 1.9M▲ 96.6% | -2.91M▼ 253.4% | 4.29M▲ 247.5% |
| Gross Margin % | -1929.75% | -1190.79% | - | 100% | 100% | 68.18% | 54.14% | - | 73.68% |
| Gross Profit Growth % | -65.39% | -121.03% | -36.04% | 120.59% | -70% | -67.87% | 96.58% | -253.4% | 247.51% |
| Operating Expenses | 28.67M | 61.16M | 28.52M | 91.42M | 92.84M | 51.88M | 49.03M | 61.3M | 93.74M |
| OpEx % of Revenue | 3425.69% | 2040.16% | - | 914.2% | 3094.53% | 3668.95% | 1400.86% | - | 1610.58% |
| Selling, General & Admin | 10.94M | 20.11M | 20.7M | 23.78M | 21.64M | 17.26M | 19M | 29.85M | 65.03M |
| SG&A % of Revenue | 1307.41% | 670.65% | - | 237.79% | 721.47% | 1220.37% | 542.97% | - | 1117.37% |
| Research & Development | 16.99M | 38.7M | 53.77M | 30.14M | 38.73M | 28.96M | 31.09M | 34.36M | 26.81M |
| R&D % of Revenue | 2029.75% | 1290.79% | - | 301.39% | 1290.87% | 2048.44% | 888.31% | - | 460.69% |
| Other Operating Expenses | 741K | 2.36M | -45.95M | 37.5M | 32.47M | 5.66M | -1.06M | -2.91M | 1.89M |
| Operating Income | -27.84M▲ 0% | -58.17M▼ 109.0% | -77.09M▼ 32.5% | -81.42M▼ 5.6% | -89.84M▼ 10.3% | -50.91M▲ 43.3% | -47.13M▲ 7.4% | -64.21M▼ 36.2% | -89.45M▼ 39.3% |
| Operating Margin % | -3325.69% | -1940.16% | - | -814.2% | -2994.53% | -3600.78% | -1346.71% | - | -1536.91% |
| Operating Income Growth % | -16.56% | -108.96% | -32.53% | -5.62% | -10.34% | 43.32% | 7.42% | -36.23% | -39.3% |
| EBITDA | -27.09M | -55.81M | -69.27M | -75.82M | -85.37M | -46.34M | -43.94M | -61.3M | -85.89M |
| EBITDA Margin % | -3237.16% | -1861.44% | - | -758.19% | -2845.73% | -3277.09% | -1255.34% | - | -1475.69% |
| EBITDA Growth % | -17.52% | -105.96% | -24.13% | -9.45% | -12.6% | 45.72% | 5.18% | -39.53% | -40.1% |
| D&A (Non-Cash Add-back) | 741K | 2.36M | 7.82M | 5.6M | 4.46M | 4.58M | 3.2M | 2.91M | 3.56M |
| EBIT | -27.32M | -56.67M | -77.09M | -80.12M | -81.28M | -38.96M | -53.77M | -59.53M | -89.45M |
| Net Interest Income | 517K | 1.5M | 808K | -2.81M | -3.62M | -305K | 1.7M | 38K | 1.82M |
| Interest Income | 525K | 1.51M | 1.21M | 1.3M | 40K | 431K | 2.12M | 4.25M | 5.56M |
| Interest Expense | 8K | 11K | 400K | 4.12M | 3.66M | 736K | 418K | 4.21M | 3.74M |
| Other Income/Expense | 517K | 1.5M | 808K | -2.81M | 4.9M | 11.22M | -7.05M | 477K | 160.73M |
| Pretax Income | -27.32M▲ 0% | -56.67M▼ 107.4% | -76.28M▼ 34.6% | -84.23M▼ 10.4% | -84.94M▼ 0.8% | -39.7M▲ 53.3% | -54.19M▼ 36.5% | -63.73M▼ 17.6% | 71.28M▲ 211.8% |
| Pretax Margin % | -3263.92% | -1890.29% | - | -842.34% | -2831.2% | -2807.36% | -1548.23% | - | 1224.79% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0.14% |
| Net Income | -27.32M▲ 0% | -56.67M▼ 107.4% | -76.28M▼ 34.6% | -84.23M▼ 10.4% | -84.94M▼ 0.8% | -39.7M▲ 53.3% | -54.19M▼ 36.5% | -63.73M▼ 17.6% | 71.18M▲ 211.7% |
| Net Margin % | -3263.92% | -1890.29% | - | -842.34% | -2831.2% | -2807.36% | -1548.23% | - | 1223.08% |
| Net Income Growth % | -24.9% | -107.44% | -34.61% | -10.42% | -0.83% | 53.26% | -36.51% | -17.62% | 211.69% |
| Net Income (Continuing) | -27.32M | -56.67M | -76.28M | -84.23M | -84.94M | -39.7M | -54.19M | -63.73M | 71.18M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -16.40▲ 0% | -29.81▼ 81.8% | -38.07▼ 27.7% | -22.75▲ 40.2% | -21.50▲ 5.5% | -5.53▲ 74.3% | -2.53▲ 54.2% | -1.55▲ 38.7% | 1.01▲ 165.2% |
| EPS Growth % | -2.5% | -81.77% | -27.71% | 40.24% | 5.49% | 74.28% | 54.25% | 38.74% | 165.16% |
| EPS (Basic) | -16.40 | -29.81 | -38.07 | -22.75 | -21.50 | -5.53 | -2.53 | -1.55 | 1.34 |
| Diluted Shares Outstanding | 1.67M | 1.9M | 2.01M | 3.71M | 3.94M | 7.86M | 21.38M | 41.05M | 66.14M |
| Basic Shares Outstanding | 1.67M | 1.9M | 2.01M | 3.71M | 3.94M | 7.86M | 21.38M | 41.05M | 52.95M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
ABEO Balance Sheet
Abeona Therapeutics Inc. (ABEO) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 140.59M | 88.85M | 132.39M | 97.74M | 56.29M | 53.1M | 55.74M | 100.85M | 204.91M |
| Cash & Short-Term Investments | 137.75M | 84.97M | 129.26M | 95.03M | 45.02M | 52.15M | 52.23M | 97.72M | 191.4M |
| Cash Only | 137.75M | 18.75M | 129.26M | 12.6M | 32.94M | 14.22M | 14.47M | 23.36M | 78.44M |
| Short-Term Investments | 0 | 66.22M | 0 | 82.44M | 12.09M | 37.93M | 37.75M | 74.36M | 112.97M |
| Accounts Receivable | 107K | 81K | 0 | 0 | 3M | 188K | 2.44M | 1.65M | 6.71M |
| Days Sales Outstanding | 46.66 | 9.86 | - | - | 365 | 48.53 | 254.87 | - | 421.13 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.49M |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | 1.31K |
| Other Current Assets | 0 | 0 | 0 | 0 | 891K | 762K | 338K | 1.48M | 1.29M |
| Total Non-Current Assets | 38.17M | 85.55M | 90.99M | 53.46M | 23.29M | 11.12M | 8.27M | 8.08M | 14.66M |
| Property, Plant & Equipment | 1.37M | 9.44M | 21.2M | 18.35M | 21.74M | 11.07M | 7.99M | 7.98M | 13.88M |
| Fixed Asset Turnover | 0.61x | 0.32x | - | 0.54x | 0.14x | 0.13x | 0.44x | - | 0.42x |
| Goodwill | 32.47M | 32.47M | 32.47M | 32.47M | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 3.98M | 43.04M | 36.18M | 1.5M | 1.38M | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 357K | 597K | 1.14M | 1.14M | 168K | 43K | 277K | 96K | 781K |
| Total Assets | 178.77M▲ 0% | 174.4M▼ 2.4% | 223.38M▲ 28.1% | 151.2M▼ 32.3% | 79.59M▼ 47.4% | 64.21M▼ 19.3% | 64M▼ 0.3% | 108.93M▲ 70.2% | 219.57M▲ 101.6% |
| Asset Turnover | 0.00x | 0.02x | - | 0.07x | 0.04x | 0.02x | 0.05x | - | 0.03x |
| Asset Growth % | 60.97% | -2.44% | 28.09% | -32.31% | -47.36% | -19.31% | -0.33% | 70.2% | 101.57% |
| Total Current Liabilities | 5.61M | 20.35M | 38.7M | 41.96M | 16.62M | 7.78M | 13.42M | 16.59M | 29.57M |
| Accounts Payable | 1.88M | 6.12M | 3.76M | 4.7M | 4.33M | 1.81M | 1.86M | 3.44M | 7.89M |
| Days Payables Outstanding | 40.41 | 57.74 | 28.28 | - | - | 1.47K | 422.54 | 432.05 | 1.88K |
| Short-Term Debt | 0 | 10M | 0 | 330K | 0 | 0 | 0 | 5.93M | 13.09M |
| Deferred Revenue (Current) | 3.21M | 296K | 296K | 296K | 296K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | -10M | 0 | 0 | 1.79M | 2.8M | 3.69M | 4.46M | 8.47M |
| Current Ratio | 25.07x | 4.37x | 3.42x | 2.33x | 3.39x | 6.83x | 4.15x | 6.08x | 6.93x |
| Quick Ratio | 25.07x | 4.37x | 3.42x | 2.33x | 3.39x | 6.83x | 4.15x | 6.08x | 6.74x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | -149.72 |
| Total Non-Current Liabilities | 3.06M | 20M | 6.25M | 6.69M | 20.59M | 29.67M | 35.75M | 48.31M | 30.78M |
| Long-Term Debt | 0 | 20M | 0 | 1.43M | 0 | 0 | 0 | 13.04M | 7.81M |
| Capital Lease Obligations | 0 | 0 | 6.25M | 5.26M | 7.56M | 5.85M | 4.4M | 3.26M | 4.07M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 13.04M | 23.82M | 31.35M | 32.01M | 18.9M |
| Total Liabilities | 8.67M | 40.35M | 44.95M | 48.65M | 37.22M | 37.45M | 49.18M | 64.9M | 60.35M |
| Total Debt | 0 | 30M | 7.95M | 8.73M | 9.38M | 7.63M | 5.4M | 23.05M | 24.97M |
| Net Debt | -137.75M | 11.25M | -121.31M | -3.87M | -23.56M | -6.59M | -9.07M | -309K | -53.47M |
| Debt / Equity | - | 0.22x | 0.04x | 0.09x | 0.22x | 0.29x | 0.36x | 0.52x | 0.16x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -3479.50x | -5287.82x | -192.73x | -19.79x | -24.57x | -69.18x | -112.76x | -15.26x | -23.92x |
| Total Equity | 170.1M▲ 0% | 134.04M▼ 21.2% | 178.43M▲ 33.1% | 102.55M▼ 42.5% | 42.37M▼ 58.7% | 26.76M▼ 36.8% | 14.83M▼ 44.6% | 44.03M▲ 197.0% | 159.22M▲ 261.6% |
| Equity Growth % | 71.65% | -21.2% | 33.11% | -42.53% | -58.69% | -36.84% | -44.6% | 196.99% | 261.6% |
| Book Value per Share | 102.16 | 70.51 | 88.59 | 27.66 | 10.76 | 3.40 | 0.69 | 1.07 | 2.41 |
| Total Shareholders' Equity | 170.1M | 134.04M | 178.43M | 102.55M | 42.37M | 26.76M | 14.83M | 44.03M | 159.22M |
| Common Stock | 469K | 479K | 836K | 961K | 1.47M | 177K | 265K | 457K | 550K |
| Retained Earnings | -359.79M | -410.19M | -486.47M | -570.7M | -655.64M | -695.34M | -749.52M | -813.26M | -742.08M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | -10K | -27K | -129K | -66K | 8K | 138K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ABEO Cash Flow Statement
Abeona Therapeutics Inc. (ABEO) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -22.93M | -39.11M | -62.82M | -35.02M | -65.67M | -43.48M | -37.01M | -56.02M | -76.33M |
| Operating CF Margin % | -2740.14% | -1304.57% | - | -350.19% | -2188.83% | -3075.18% | -1057.4% | - | -1311.44% |
| Operating CF Growth % | -76.23% | -70.53% | -60.62% | 44.26% | -87.51% | 33.78% | 14.89% | -51.36% | -36.26% |
| Net Income | -27.32M | -56.67M | -76.28M | -84.23M | -84.94M | -39.7M | -54.19M | -63.73M | 71.18M |
| Depreciation & Amortization | 741K | 2.36M | 8.68M | 5.6M | 4.46M | 4.58M | 3.2M | 2.91M | 3.56M |
| Stock-Based Compensation | 5.92M | 8.87M | 8.24M | 8.19M | 8.92M | 3.05M | 4.77M | 6.63M | 10.78M |
| Deferred Taxes | -1.4M | -1.31M | 0 | 32.92M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.27M | 688K | 101K | 877K | 24.15M | -5.52M | 11M | 2.57M | -156.46M |
| Working Capital Changes | -2.15M | 6.96M | -3.55M | 1.63M | -18.26M | -5.89M | -1.79M | -4.38M | -5.39M |
| Change in Receivables | 17K | 26K | 81K | 0 | -3M | 2.81M | 0 | 792K | -5.06M |
| Change in Inventory | -2.58M | -1.03M | -81K | 0 | 0 | 0 | 0 | 0 | -5.49M |
| Change in Payables | -1.3M | 7.67M | -1.71M | -2.18M | -15.59M | -9.11M | 2.04M | -3.49M | 6.54M |
| Cash from Investing | -860K | -85.09M | 59.98M | -83.71M | 66.06M | -23.96M | 208K | -39.24M | 105.03M |
| Capital Expenditures | -860K | -19.49M | -6.51M | -1.34M | -4.15M | -130K | -331K | -2.45M | -7.97M |
| CapEx % of Revenue | 102.75% | 650.23% | - | 13.36% | 138.37% | 9.19% | 9.46% | - | 137.03% |
| Acquisitions | 0 | 19.49M | 0 | 1.34M | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -19.49M | 0 | -1.34M | 0 | 1.73M | 204K | 18K | 152.37M |
| Cash from Financing | 92.4M | 5.48M | 113.9M | 1.94M | 24.86M | 43.17M | 37.06M | 104.14M | 26.04M |
| Debt Issued (Net) | 0 | 0 | 0 | 1.76M | 0 | 0 | 0 | 20M | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 6.23M | 0 | 969K | 177K | 831K | -5K | -332K | -1.49M | -37K |
| Net Change in Cash | 68.61M▲ 0% | -118.72M▼ 273.0% | 111.06M▲ 193.5% | -116.8M▼ 205.2% | 25.26M▲ 121.6% | -24.27M▼ 196.1% | 256K▲ 101.1% | 8.88M▲ 3370.3% | 54.74M▲ 516.2% |
| Free Cash Flow | -23.8M▲ 0% | -58.6M▼ 146.3% | -69.33M▼ 18.3% | -36.35M▲ 47.6% | -69.82M▼ 92.0% | -43.61M▲ 37.5% | -37.34M▲ 14.4% | -58.46M▼ 56.6% | -84.3M▼ 44.2% |
| FCF Margin % | -2842.89% | -1954.8% | - | -363.55% | -2327.2% | -3084.37% | -1066.86% | - | -1448.47% |
| FCF Growth % | -75.83% | -146.29% | -18.3% | 47.56% | -92.04% | 37.53% | 14.38% | -56.56% | -44.2% |
| FCF per Share | -14.29 | -30.83 | -34.42 | -9.81 | -17.73 | -5.55 | -1.75 | -1.42 | -1.27 |
| FCF Conversion (FCF/Net Income) | 0.84x | 0.69x | 0.82x | 0.42x | 0.77x | 1.10x | 0.68x | 0.88x | -1.07x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.67M | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 14K | 7K | 0 |
ABEO Key Ratios
Abeona Therapeutics Inc. (ABEO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -26.22% | -20.3% | -37.27% | -48.82% | -59.96% | -117.22% | -114.85% | -260.6% | -216.57% | 70.05% |
| Return on Invested Capital (ROIC) | -58.21% | -67.02% | -49.11% | -57.13% | -78.38% | -114.69% | -195.93% | -272.73% | -194.68% | -89.77% |
| Gross Margin | -1098.54% | -1929.75% | -1190.79% | - | 100% | 100% | 68.18% | 54.14% | - | 73.68% |
| Net Margin | -2460.4% | -3263.92% | -1890.29% | - | -842.34% | -2831.2% | -2807.36% | -1548.23% | - | 1223.08% |
| Debt / Equity | - | - | 0.22x | 0.04x | 0.09x | 0.22x | 0.29x | 0.36x | 0.52x | 0.16x |
| Interest Coverage | -3980.17x | -3479.50x | -5287.82x | -192.73x | -19.79x | -24.57x | -69.18x | -112.76x | -15.26x | -23.92x |
| FCF Conversion | 0.59x | 0.84x | 0.69x | 0.82x | 0.42x | 0.77x | 1.10x | 0.68x | 0.88x | -1.07x |
| Revenue Growth | -14.52% | -5.85% | 258.18% | -100% | - | -70% | -52.87% | 147.52% | -100% | - |
ABEO SEC Filings & Documents
Abeona Therapeutics Inc. (ABEO) SEC filings — annual & quarterly reports (10-K, 10-Q)
ABEO Frequently Asked Questions
Abeona Therapeutics Inc. (ABEO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Abeona Therapeutics Inc. (ABEO) reported $5.8M in revenue for fiscal year 2025. This represents a 3385% increase from $0.2M in 1996.
Abeona Therapeutics Inc. (ABEO) grew revenue by 0.0% over the past year. Growth has been modest.
Yes, Abeona Therapeutics Inc. (ABEO) is profitable, generating $71.2M in net income for fiscal year 2025 (1223.1% net margin).
Dividend & Returns
Abeona Therapeutics Inc. (ABEO) has a return on equity (ROE) of 70.0%. This is excellent, indicating efficient use of shareholder capital.
Abeona Therapeutics Inc. (ABEO) had negative free cash flow of $84.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More ABEO
Abeona Therapeutics Inc. (ABEO) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates